Cardiff Oncology (CRDF) Depreciation & Amortization (CF) (2011 - 2026)

Cardiff Oncology has reported Depreciation & Amortization (CF) for 15 years, with the latest figure at $88000.0 in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 8.33% year-over-year to $88000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $364000.0 (down 9.9% YoY) and the FY2025 annual result came in at $364000.0, down 9.9% from the prior year.
• Depreciation & Amortization (CF) retreated to $88000.0 in Q4 2025 per CRDF's latest filing, from $89000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $119000.0 in Q1 2021 and troughed at $31000.0 in Q1 2022.
• A 5-year average of $92650.0 and a median of $97000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) tumbled 73.95% in 2022, then soared 190.32% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $113000.0 in 2021, then retreated by 23.89% to $86000.0 in 2022, then gained by 19.77% to $103000.0 in 2023, then declined by 6.8% to $96000.0 in 2024, then fell by 8.33% to $88000.0 in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $88000.0, $89000.0, and $94000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.